Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns

fiercebiotechMay 04, 2018

Tag: Regeneron , halts , osteoarthritis drug

PharmaSources Customer Service